Sec Form 13D Filing - Frazier Life Sciences VIII L.P. @ Sierra Oncology Inc.

Sec Form 13D Filing - Frazier Life Sciences VIII L.P. filing for Sierra Oncology Inc. (SRRA) - 2020-04-29

Insider filing report for Changes in Beneficial Ownership

Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.

"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13D

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)*

Sierra Oncology, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

82640U404

(CUSIP Number)

Steve R. Bailey

Frazier Healthcare Partners

601 Union Street, Suite 3200

Seattle, WA 98101

Telephone: (206) 621-7200

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

March 3, 2020

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 82640U404


1.		Name of Reporting Persons. Frazier Life Sciences VIII, L.P.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC USE ONLY
4.		Source of Funds (See Instructions) WC
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Delaware

(1)

Consists of 148,148 shares of Common Stock held directly by Frazier Life Sciences VIII, L.P. FHM Life Sciences VIII, L.P. is the general partner of Frazier Life Sciences VIII, L.P. and FHM Life Sciences VIII, L.L.C. is the general partner of FHM Life Sciences VIII, L.P. James N. Topper and Patrick J. Heron are the sole members of FHM Life Sciences VIII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences VIII, L.P.

(2)	Based on 10,395,732 shares of Common Stock outstanding on February 26, 2020 as set forth in the Issuer’s Form 10-K filed on March 3, 2020.

CUSIP No. 82640U404


1.		Name of Reporting Persons. FHM Life Sciences VIII, L.P.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC USE ONLY
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Delaware

(1)

(2)	Based on 10,395,732 shares of Common Stock outstanding on February 26, 2020 as set forth in the Issuer’s Form 10-K filed on March 3, 2020.

CUSIP No. 82640U404


1.		Name of Reporting Persons. FHM Life Sciences VIII, L.L.C.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC USE ONLY
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Delaware

(1)

(2)	Based on 10,395,732 shares of Common Stock outstanding on February 26, 2020 as set forth in the Issuer’s Form 10-K filed on March 3, 2020.

CUSIP No. 82640U404


1.		Name of Reporting Persons. Frazier Healthcare VI, L.P.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC USE ONLY
4.		Source of Funds (See Instructions) WC
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Delaware

(1)

Consists of 54,655 shares of Common Stock held directly by Frazier Healthcare VI, L.P. FHM VI, L.P. is the general partner of Frazier Healthcare VI, L.P. and FHM VI, L.L.C. is the general partner of FHM VI, L.P. James N. Topper, Patrick J. Heron, Alan Frazier, Nader Naini and Nathan Every are the members of FHM VI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Healthcare VI, L.P.

(2)	Based on 10,395,732 shares of Common Stock outstanding on February 26, 2020 as set forth in the Issuer’s Form 10-K filed on March 3, 2020.

CUSIP No. 82640U404


1.		Name of Reporting Persons. FHM VI, L.P.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC USE ONLY
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Delaware

(1)

(2)	Based on 10,395,732 shares of Common Stock outstanding on February 26, 2020 as set forth in the Issuer’s Form 10-K filed on March 3, 2020.

CUSIP No. 82640U404


1.		Name of Reporting Persons. FHM VI, L.L.C.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC USE ONLY
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Delaware

(1)

(2)	Based on 10,395,732 shares of Common Stock outstanding on February 26, 2020 as set forth in the Issuer’s Form 10-K filed on March 3, 2020.

CUSIP No. 82640U404


1.		Name of Reporting Persons. James N. Topper
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC USE ONLY
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization United States Citizen

(1)

Consists of 148,148 shares of Common Stock held directly by Frazier Life Sciences VIII, L.P. and 54,655 shares of Common Stock held directly by Frazier Healthcare VI, L.P. FHM Life Sciences VIII, L.P. is the general partner of Frazier Life Sciences VIII, L.P. and FHM Life Sciences VIII, L.L.C. is the general partner of FHM Life Sciences VIII, L.P. James N. Topper and Patrick J. Heron are the sole members of FHM Life Sciences VIII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences VIII, L.P. FHM VI, L.P. is the general partner of Frazier Healthcare VI, L.P. and FHM VI, L.L.C. is the general partner of FHM VI, L.P. James N. Topper, Patrick J. Heron, Alan Frazier, Nader Naini and Nathan Every are the members of FHM VI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Healthcare VI, L.P.

(2)	Based on 10,395,732 shares of Common Stock outstanding on February 26, 2020 as set forth in the Issuer’s Form 10-K filed on March 3, 2020.

CUSIP No. 82640U404


1.		Name of Reporting Persons. Patrick J. Heron
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC USE ONLY
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization United States Citizen

(1)

(2)	Based on 10,395,732 shares of Common Stock outstanding on February 26, 2020 as set forth in the Issuer’s Form 10-K filed on March 3, 2020.

CUSIP No. 82640U404


1.		Name of Reporting Persons. Alan Frazier
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC USE ONLY
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization United States Citizen

(1)

(2)	Based on 10,395,732 shares of Common Stock outstanding on February 26, 2020 as set forth in the Issuer’s Form 10-K filed on March 3, 2020.

CUSIP No. 82640U404


1.		Name of Reporting Persons. Nader Naini
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC USE ONLY
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization United States Citizen

(1)

(2)	Based on 10,395,732 shares of Common Stock outstanding on February 26, 2020 as set forth in the Issuer’s Form 10-K filed on March 3, 2020.

CUSIP No. 82640U404


1.		Name of Reporting Persons. Nathan Every
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC USE ONLY
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization United States Citizen

(1)

(2)	Based on 10,395,732 shares of Common Stock outstanding on February 26, 2020 as set forth in the Issuer’s Form 10-K filed on March 3, 2020.

Item 1.

Security and Issuer.

This Amendment No. 2 (“Amendment No. 2”) to Schedule 13D amends the statement on Schedule 13D filed on February 24, 2017 (the “Original Schedule 13D”), as amended by Amendment No. 1 as filed with the Securities and Exchange Commission on November 14, 2018 (“Amendment 1” and together with the Original Schedule 13D and this Amendment No. 2, the “Schedule 13D”) with respect to the Common Stock of Sierra Oncology, Inc. (the “Issuer”), having its principal executive office at 2150 – 885 West Georgia Street, Vancouver, British Columbia, Canada. Except as otherwise specified in Amendment No. 2, all items in the Original Schedule 13D, as amended by Amendment 1, are unchanged. All capitalized terms used in this Amendment No. 2 and not otherwise defined herein have the meanings ascribed to such terms in the Original Schedule 13D, as previously amended.

The Reporting Persons are filing this Amendment No. 2 to report a decrease in the percentage of the class beneficially owned by the Reporting Persons due to an increase in the aggregate number of outstanding securities of the Issuer. The Reporting Persons are no longer beneficial owners of more than five percent of the Common Stock of the Issuer.

Item 5.

Interest in Securities of the Issuer

Item 5 of the Original Schedule 13D, as previously amended, is hereby amended and restated as follows:

(a)

FLS VIII is the record owner of the FLS VIII Shares. As the sole general partner of FLS VIII, FHM LS VIII, L.P. may be deemed to beneficially own the FLS VIII Shares. As the sole general partner of FM VIII L.P., FM VI LLC may be deemed to beneficially own the FLS VIII Shares. As individual members of FM VI LLC, each of the Topper and Heron may be deemed to beneficially own the FLS VIII Shares. Each Reporting Person disclaims beneficial ownership of all FLS VIII Shares other than those shares which such person owns of record.

FH VI is the record owner of the FH VI Shares. As the sole general partner of FH VI, FM VI L.P. may be deemed to beneficially own the FH VI Shares. As the sole general partner of FM VI L.P., FM VI LLC may be deemed to beneficially own the FH VI Shares. As individual members of FM VI LLC, each of the Topper, Heron, Frazier, Naini and Every may be deemed to beneficially own the FH VI Shares. Each Reporting Person disclaims beneficial ownership of all FH VI Shares other than those shares which such person owns of record.

The percentage of outstanding shares of Common Stock of the Issuer, which may be deemed to be beneficially owned by each Reporting Person, is set forth on Line 13 of such Reporting Person’s cover sheet. Such percentage was calculated based on the 10,395,732 shares of Common Stock outstanding on February 26, 2020 as set forth in the Issuer’s Form 10-K filed on March 3, 2020.

(b)

Regarding the number of shares as to which such person has:

Sole power to vote or to direct the vote: See line 7 of cover sheets.

Shared power to vote or to direct the vote: See line 8 of cover sheets.

Sole power to dispose or to direct the disposition: See line 9 of cover sheets.

Shared power to dispose or to direct the disposition: See line 10 of cover sheets.

(c)

Not applicable.

(d)

No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the FH Shares beneficially owned by any of the Reporting Persons.

(e)

Not applicable.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


Date: April 28, 2020	FRAZIER LIFE SCIENCES VIII, L.P.
	By	FHM Life Sciences VIII, L.P., its general partner
	By	FHM Life Sciences VIII, L.L.C., its general partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: April 28, 2020	FHM LIFE SCIENCES VIII, L.P.
	By	FHM Life Sciences VIII, L.L.C., its general partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: April 28, 2020	FHM LIFE SCIENCES VIII, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: April 28, 2020	FRAZIER HEALTHCARE VI, L.P .
	By:	FHM VI, L.P., its General Partner
	By:	FHM VI, LLC, its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: April 28, 2020	FHM VI, L.P.
	By:	FHM VI, LLC, its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: April 28, 2020	FHM VI, LLC

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer



Date: April 28, 2020	By:	*
		James N. Topper

Date: April 28, 2020	By:	*
		Patrick J. Heron

Date: April 28, 2020	By:	*
		Alan Frazier

Date: April 28, 2020	By:	*
		Nader Naini

Date: April 28, 2020	By:	*
		Nathan Every

Date: April 28, 2020	*By:	/s/ Steve R. Bailey
		Steve R. Bailey, as Attorney-in-Fact

This Schedule 13D was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on February 24, 2017.

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With:

Sole Voting Power

0 shares

Shared Voting Power

148,148 shares (1)

Sole Dispositive Power

0 shares

Shared Dispositive Power

148,148 shares (1)